Research programme: CNS disorder liposomal therapeutics - Sihuan/BBB TherapeuticsAlternative Names: Glutathione-pegylated liposomal therapeutics - Sihuan/to-BBB
Latest Information Update: 03 Oct 2014
$50 / €47 *
At a glance
- Originator Sihuan Pharmaceutical Holdings Group; to-BBB technologies
- Developer BBB Therapeutics; Sihuan Pharmaceutical Holdings Group
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research CNS disorders
Most Recent Events
- 30 Sep 2014 to-BBB technologies is now called BBB Therapeutics
- 12 Feb 2014 Profile released, added ADMN.
- 11 Dec 2013 Early research in CNS disorders in China (Parenteral)